Leerink Partnrs Predicts Stronger Earnings for AnaptysBio

AnaptysBio, Inc. (NASDAQ:ANAB) – Analysts at Leerink Partnrs raised their FY2024 EPS estimates for shares of AnaptysBio in a research report issued to clients and investors on Tuesday, November 5th. Leerink Partnrs analyst D. Risinger now forecasts that the biotechnology company will post earnings of ($5.76) per share for the year, up from their prior estimate of ($6.48). The consensus estimate for AnaptysBio’s current full-year earnings is ($6.84) per share. Leerink Partnrs also issued estimates for AnaptysBio’s Q4 2024 earnings at ($1.30) EPS, Q1 2025 earnings at ($1.88) EPS, Q2 2025 earnings at ($1.69) EPS, Q3 2025 earnings at ($1.75) EPS, Q4 2025 earnings at ($1.07) EPS, FY2025 earnings at ($6.01) EPS, FY2026 earnings at ($4.16) EPS, FY2027 earnings at ($3.41) EPS and FY2028 earnings at ($2.87) EPS.

AnaptysBio (NASDAQ:ANAB) last issued its earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) EPS for the quarter, topping the consensus estimate of ($1.72) by $0.58. The business had revenue of $30.02 million during the quarter, compared to the consensus estimate of $7.92 million. AnaptysBio had a negative return on equity of 255.68% and a negative net margin of 558.25%.

Several other research analysts have also commented on ANAB. JPMorgan Chase & Co. boosted their price objective on AnaptysBio from $69.00 to $75.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. UBS Group lifted their target price on shares of AnaptysBio from $23.00 to $33.00 and gave the company a “neutral” rating in a research report on Wednesday, October 30th. Wedbush reissued an “outperform” rating and issued a $42.00 price target on shares of AnaptysBio in a report on Wednesday. Guggenheim raised their price objective on shares of AnaptysBio from $75.00 to $90.00 and gave the company a “buy” rating in a research report on Monday, October 21st. Finally, HC Wainwright cut their target price on shares of AnaptysBio from $55.00 to $52.00 and set a “buy” rating for the company in a research report on Wednesday. Two investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, AnaptysBio currently has an average rating of “Moderate Buy” and a consensus price target of $55.45.

AnaptysBio Stock Down 0.8 %

AnaptysBio stock opened at $21.31 on Friday. The business has a 50-day simple moving average of $32.66 and a 200 day simple moving average of $29.84. AnaptysBio has a 52 week low of $13.36 and a 52 week high of $41.31. The stock has a market cap of $584.53 million, a price-to-earnings ratio of -3.36 and a beta of -0.24.

Hedge Funds Weigh In On AnaptysBio

Hedge funds and other institutional investors have recently modified their holdings of the company. Jennison Associates LLC purchased a new position in AnaptysBio during the 3rd quarter valued at about $8,874,000. Victory Capital Management Inc. grew its position in shares of AnaptysBio by 677.9% in the 3rd quarter. Victory Capital Management Inc. now owns 237,250 shares of the biotechnology company’s stock worth $7,948,000 after buying an additional 206,750 shares during the last quarter. GSA Capital Partners LLP bought a new stake in shares of AnaptysBio in the 3rd quarter worth approximately $574,000. China Universal Asset Management Co. Ltd. increased its stake in shares of AnaptysBio by 81.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 5,808 shares of the biotechnology company’s stock valued at $195,000 after buying an additional 2,600 shares during the period. Finally, Values First Advisors Inc. bought a new position in shares of AnaptysBio during the third quarter valued at approximately $49,000.

Insiders Place Their Bets

In other news, insider Paul F. Lizzul sold 1,500 shares of the firm’s stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $38.67, for a total transaction of $58,005.00. Following the transaction, the insider now directly owns 15,398 shares of the company’s stock, valued at approximately $595,440.66. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CFO Dennis Mulroy sold 12,220 shares of AnaptysBio stock in a transaction on Monday, September 16th. The shares were sold at an average price of $39.91, for a total value of $487,700.20. Following the transaction, the chief financial officer now directly owns 4,744 shares of the company’s stock, valued at $189,333.04. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Paul F. Lizzul sold 1,500 shares of the stock in a transaction on Monday, September 23rd. The shares were sold at an average price of $38.67, for a total transaction of $58,005.00. Following the sale, the insider now directly owns 15,398 shares of the company’s stock, valued at $595,440.66. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 22,440 shares of company stock valued at $892,936 over the last three months. Insiders own 33.70% of the company’s stock.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.